Zurich Cantonal Bank
MRSN

Zurich Cantonal Bank’s Mersana Therapeutics MRSN Stock Holding History

Zurich Cantonal Bank’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-698
Closed -$22.2K – 2768
2023
Q3 		$22.2K Hold
698
– – ﹤0.01% 2700
2023
Q2 		$57.4K Buy
698
+208
+42% +$30.4K ﹤0.01% 2570
2023
Q1 		$50.3K Hold
490
– – ﹤0.01% 2594
2022
Q4 		$71.8K Buy
490
+200
+69% +$33.8K ﹤0.01% 2470
2022
Q3 		$49K Hold
290
– – ﹤0.01% 2598
2022
Q2 		$34K Hold
290
– – ﹤0.01% 2692
2022
Q1 		$29K Sell
290
-103
-26% -$12K ﹤0.01% 2616
2021
Q4 		$61K Sell
393
-11
-3% -$2.14K ﹤0.01% 2676
2021
Q3 		$95K Buy
404
+1
+0.2% +$292 ﹤0.01% 2371
2021
Q2 		$137K Buy
403
+5
+1% +$1.89K ﹤0.01% 2055
2021
Q1 		$161K Buy
398
+108
+37% +$52.4K ﹤0.01% 1904
2020
Q4 		$193K Buy
290
+63
+28% +$35K ﹤0.01% 1868
2020
Q3 		$106K Hold
227
– – ﹤0.01% 1956
2020
Q2 		$133K Buy
+227
New +$77.5K ﹤0.01% 1793

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Zurich Cantonal Bank's MRSN Position: Q4 2023 in Review

Zurich Cantonal Bank sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 698 shares — an estimated $22.2K sold.

Zurich Cantonal Bank first reported a position in MRSN in Q2 2020 and held it in 14 quarters. The position peaked at $193K in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Zurich Cantonal Bank reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Zurich Cantonal Bank sold 698 Mersana Therapeutics shares in Q4 2023, an estimated $22.2K.
  • Zurich Cantonal Bank first reported a position in Mersana Therapeutics in Q2 2020 and held it in 14 quarters.
  • Zurich Cantonal Bank's Mersana Therapeutics position peaked at $193K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Zurich Cantonal Bank's 13F filing for Q4 2023, filed 30 Jan 2024.